These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20400153)

  • 1. Urinary and serum carbohydrate antigen 19-9 as a biomarker in ureteropelvic junction obstruction in children.
    Kajbafzadeh AM; Elmi A; Talab SS; Emami H; Esfahani SA; Saeedi P
    J Urol; 2010 Jun; 183(6):2353-60. PubMed ID: 20400153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstructed versus dilated nonobstructed kidneys in children with congenital ureteropelvic junction narrowing: role of urinary tubular enzymes.
    Taha MA; Shokeir AA; Osman HG; Abd El-Aziz Ael-A; Farahat SE
    J Urol; 2007 Aug; 178(2):640-6. PubMed ID: 17574624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of ureteropelvic junction obstruction in children: role of endothelin-1 in voided urine.
    Taha MA; Shokeir AA; Osman HG; Abd el-Aziz Ael-A; Farahat SE
    Urology; 2007 Mar; 69(3):560-4; discussion 564-5. PubMed ID: 17382166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of serum and urinary carbohydrate antigen 19-9 in the management of patients with antenatal hydronephrosis.
    Atar A; Oktar T; Kucukgergin C; Kalelioglu I; Seckin S; Ander H; Ziylan O; Kadioglu TC
    J Pediatr Urol; 2015 Jun; 11(3):133.e1-5. PubMed ID: 25824879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvi-ureteric junction obstruction in children: the role of urinary transforming growth factor-beta and epidermal growth factor.
    Taha MA; Shokeir AA; Osman HG; Abd El-Aziz Ael-A; Farahat SE
    BJU Int; 2007 Apr; 99(4):899-903. PubMed ID: 17378848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of urinary tubular enzymes in evaluation of children with ureteropelvic junction narrowing under conservative management.
    Shokeir AA; Taha MA
    Urology; 2009 May; 73(5):1016-20. PubMed ID: 19394498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment.
    Peters CA
    J Urol; 2010 Jun; 183(6):2359. PubMed ID: 20400160
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment.
    El-Ghoneimi A
    J Urol; 2010 Jun; 183(6):2359. PubMed ID: 20400159
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply by authors.
    Kajbafzadeh AM; Elmi A; Talab SS; Emami H; Esfahani SA; Saeedi P
    J Urol; 2010 Jun; 183(6):2359-60. PubMed ID: 20400158
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary carbohydrate antigen 19-9/creatinine ratio: A non-invasive marker for follow-up of unilateral ureteropelvic junction obstruction in children.
    Alizadeh F; Taefnia AM; Haghdani S
    J Pediatr Urol; 2018 Feb; 14(1):62.e1-62.e4. PubMed ID: 29079483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for recurrent ureteropelvic junction obstruction after open pyeloplasty in a large pediatric cohort.
    Braga LH; Lorenzo AJ; Bägli DJ; Keays M; Farhat WA; Khoury AE; Salle JL
    J Urol; 2008 Oct; 180(4 Suppl):1684-7; discussion 1687-8. PubMed ID: 18708226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine levels of transforming growth factor-beta 1 in children with ureteropelvic junction obstruction.
    Palmer LS; Maizels M; Kaplan WE; Firlit CF; Cheng EY
    Urology; 1997 Nov; 50(5):769-73. PubMed ID: 9372890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal pelvis cuff pyeloplasty for ureteropelvic junction obstruction for the high inserting ureter: an initial experience.
    Palmer LS; Proano JM; Palmer JS
    J Urol; 2005 Sep; 174(3):1088-90. PubMed ID: 16094065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate urinary biomarker discovery in ureteropelvic junction obstruction: a proteomic approach.
    Mesrobian HG; Mitchell ME; See WA; Halligan BD; Carlson BE; Greene AS; Wakim BT
    J Urol; 2010 Aug; 184(2):709-14. PubMed ID: 20639044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of health related quality of life for pediatric patients with ureteropelvic junction obstruction.
    Parekh AD; Thomas JC; Trusler L; Ankerst DP; Deshpande JK; Adams MC; Pope JC; Brock JW
    J Urol; 2008 Nov; 180(5):2171-5; discussion 2175-6. PubMed ID: 18804796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic pyeloplasty for secondary ureteropelvic junction obstruction.
    Sundaram CP; Grubb RL; Rehman J; Yan Y; Chen C; Landman J; McDougall EM; Clayman RV
    J Urol; 2003 Jun; 169(6):2037-40. PubMed ID: 12771713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis.
    Aybek H; Aybek Z; Sinik Z; Demir S; Sancak B; Tuncay L
    Int J Urol; 2006 Nov; 13(11):1380-4. PubMed ID: 17083387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen-to-smooth muscle ratio helps prediction of prognosis after pyeloplasty.
    Kim WJ; Yun SJ; Lee TS; Kim CW; Lee HM; Choi H
    J Urol; 2000 Apr; 163(4):1271-5. PubMed ID: 10737527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical management of congenital ureteropelvic junction obstruction: a Pediatric Health Information System database study.
    Vemulakonda VM; Cowan CA; Lendvay TS; Joyner BD; Grady RW
    J Urol; 2008 Oct; 180(4 Suppl):1689-92; discussion 1692. PubMed ID: 18708209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine interleukin-8 as a marker of vesicoureteral reflux in infants.
    Galanakis E; Bitsori M; Dimitriou H; Giannakopoulou C; Karkavitsas NS; Kalmanti M
    Pediatrics; 2006 May; 117(5):e863-7. PubMed ID: 16585276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.